Exane Derivatives’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
Other funds holding EBS
Exane Derivatives's EBS Position: Q2 2022 in Review
Exane Derivatives reduced its Emergent Biosolutions (EBS) stake by 97% in Q2 2022, selling an estimated $41.2K and leaving 39 shares worth $1.21K. The position accounts for ﹤0.01% of the portfolio, ranked #489.
Exane Derivatives first reported a position in EBS in Q4 2020 and has held it in 7 quarters since. The position peaked at $394K in Q4 2020. 231 funds tracked by Wall St. Rank hold EBS as of Q2 2022.
- Exane Derivatives held 39 shares of Emergent Biosolutions worth $1.21K as of Q2 2022.
- Exane Derivatives sold 1,206 Emergent Biosolutions shares in Q2 2022, an estimated $41.2K.
- Emergent Biosolutions made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #489 holding.
- Exane Derivatives first reported a position in Emergent Biosolutions in Q4 2020 and has held it in 7 quarters since.
- Exane Derivatives's Emergent Biosolutions position peaked at $394K in Q4 2020.
- 231 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.
Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.